Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1056/NEJMoa2016638

http://scihub22266oqcxt.onion/10.1056/NEJMoa2016638
suck pdf from google scholar
32492293!7289276!32492293
unlimited free pdf from europmc32492293    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32492293      N+Engl+J+Med 2020 ; 383 (6): 517-525
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 #MMPMID32492293
  • Boulware DR; Pullen MF; Bangdiwala AS; Pastick KA; Lofgren SM; Okafor EC; Skipper CP; Nascene AA; Nicol MR; Abassi M; Engen NW; Cheng MP; LaBar D; Lother SA; MacKenzie LJ; Drobot G; Marten N; Zarychanski R; Kelly LE; Schwartz IS; McDonald EG; Rajasingham R; Lee TC; Hullsiek KH
  • N Engl J Med 2020[Aug]; 383 (6): 517-525 PMID32492293show ga
  • BACKGROUND: Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown. METHODS: We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. RESULTS: We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was -2.4 percentage points (95% confidence interval, -7.0 to 2.2; P = 0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. CONCLUSIONS: After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).
  • |*Post-Exposure Prophylaxis[MESH]
  • |Adult[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Canada[MESH]
  • |Coronavirus Infections/*prevention & control[MESH]
  • |Double-Blind Method[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/adverse effects/*therapeutic use[MESH]
  • |Inhalation Exposure[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Occupational Exposure[MESH]
  • |Pandemics/*prevention & control[MESH]
  • |Pneumonia, Viral/*prevention & control[MESH]
  • |SARS-CoV-2[MESH]
  • |Treatment Failure[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box